MANISHA KAMAT: Open Payments
NPI 1679755128 · CHESTER, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,311 in 41 payments from 11 companies in 2025. Trend: 2023 $1,022 · 2024 $1,090 · 2025 $1,311
Food & beverage: $1,095Education: $216
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $301 |
| Teva Pharmaceuticals USA, Inc. | 4 | $275 |
| ABBVIE INC. | 8 | $212 |
| Neurocrine BioSciences, Inc. | 5 | $135 |
| Janssen Pharmaceuticals, Inc | 2 | $125 |
| Alkermes, Inc. | 3 | $74 |
| Otsuka America Pharmaceutical, Inc. | 3 | $66 |
| Axsome Therapeutics, Inc. | 2 | $49 |
| Almatica Pharma LLC | 2 | $34 |
| Lundbeck LLC | 1 | $27 |
Products named: CAPLYTA, VRAYLAR, INGREZZA, SPRAVATO, REXULTI, ARISTADA, Auvelity, UZEDY.
Industry payments across PA — which companies pay providers there.
